Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|The Lancet Oncology|2018Cited by 1k
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Claus Garbe et al.|The Lancet Oncology|2018Cited by 586
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Karl D. Lewis et al.|The Lancet Oncology|2018Cited by 216
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and managementHelen Gogas, Caroline Robert, Keith T. Flaherty et al.|European Journal of Cancer|2019Cited by 81
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanomaReinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|Annals of Oncology|2017Cited by 40